Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signaling
Medicinal Research Reviews · 2023-05 · 43 (3) · 614-682
DOI: 10.1002/med.21933 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 19.01.2023. Verfasst von Solveigh C Koeberle und 3 weiteren Autor:innen. Beteiligte Einrichtung: Michael Popp Institute, Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Tirol, Innsbruck, Austria. Hauptthemen laut MEDLINE: Ferroptosis, Neoplasms. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 396 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Phospholipid Research Center, Deutsche Forschungsgemeinschaft, Austrian Science Fund.
Abstract (Originalsprache)
Ferroptosis is an iron‐dependent cell death program that is characterized by excessive lipid peroxidation. Triggering ferroptosis has been proposed as a promising strategy to fight cancer and overcome drug resistance in antitumor therapy. Understanding the molecular interactions and structural features of ferroptosis‐inducing compounds might therefore open the door to efficient pharmacological strategies against aggressive, metastatic, and therapy‐resistant cancer. We here summarize the molecular mechanisms and structural requirements of ferroptosis‐inducing small molecules that target central players in ferroptosis. Focus is placed on (i) glutathione peroxidase (GPX) 4, the only GPX isoenzyme that detoxifies complex membrane‐bound lipid hydroperoxides, (ii) the cystine/glutamate antiporter system X c − that is central for glutathione regeneration, (iii) the redox‐protective transcription factor nuclear factor erythroid 2‐related factor (NRF2), and (iv) GPX4 repression in combination with induced heme degradation via heme oxygenase‐1. We deduce common features for efficient ferroptotic activity and highlight challenges in drug development. Moreover, we critically discuss the potential of natural products as ferroptosis‐inducing lead structures and provide a comprehensive overview of structurally diverse biogenic and bioinspired small molecules that trigger ferroptosis via iron oxidation, inhibition of the thioredoxin/thioredoxin reductase system or less defined modes of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Michael Popp Institute, Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Tirol, Innsbruck, Austria.
- Department of Molecular Nutritional Physiology, Institute of Nutritional Sciences, Friedrich Schiller University Jena, Thüringen, Jena, Germany.
- Unit of Pharmacognosy, Institute of Pharmacy, Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck, Tirol, Innsbruck, Austria.
ORCID-Profile: Andreas Koeberle
Förderung
- Phospholipid Research Center
- Deutsche Forschungsgemeinschaft
- Austrian Science Fund
- Friedrich-Schiller-Universität Jena
Zitieren
APA
Koeberle, S. C., Kipp, A. P., Stuppner, H., & Koeberle, A. (2023). Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signaling. Medicinal Research Reviews, 43(3), 614-682. https://doi.org/10.1002/med.21933
Vancouver
Koeberle SC, Kipp AP, Stuppner H, Koeberle A. Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signaling. Medicinal Research Reviews. 2023;43(3):614-682. doi:10.1002/med.21933
BibTeX
@article{Koeberle2023,
author = {Koeberle, Solveigh C and Kipp, Anna P and Stuppner, Hermann and Koeberle, Andreas},
title = {Ferroptosis‐modulating small molecules for targeting drug‐resistant cancer: Challenges and opportunities in manipulating redox signaling},
journal = {Medicinal Research Reviews},
year = {2023},
volume = {43},
number = {3},
pages = {614--682},
doi = {10.1002/med.21933}
}
EUVIMED